Annexon

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2011-01-01

Employees: 71

Market Cap: $639.2M

Website: http://www.annexonbio.com

Introduction: Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington’s and alzheimer’s disease, multiple sclerosis, glaucoma, parkinson’s disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.

Clinical Trials

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of ANX007 in Participants With Geographic Atrophy (GA)

Phase 3

Recruiting

Conditions: Geographic Atrophy

Interventions: Drug: ANX007
Other: Sham Administration

First Posted Date: 2024-07-19

Last Posted Date: 2024-12-04

Lead Sponsor: Annexon, Inc.

Target Recruit Count: 630

Registration Number: NCT06510816

Locations: 🇺🇸
Retina Consultants of Texas San Antonio, San Antonio, Texas, United States
🇺🇸
Texas Retina Associates - Fort Worth, Fort Worth, Texas, United States
🇺🇸
Retina Macula Institute of Arizona, Scottsdale, Arizona, United States

and more 45 locations

A Study of ANX009 in Adult Participants With Lupus Nephritis

Phase 1

Completed

Conditions: Lupus Nephritis

Interventions: Biological: ANX009

First Posted Date: 2023-03-22

Last Posted Date: 2024-08-22

Lead Sponsor: Annexon, Inc.

Target Recruit Count: 7

Registration Number: NCT05780515

Locations: 🇨🇳
Annexon Investigational Site 102, Taipei, Taiwan
🇵🇭
Annexon Investigational Site 201, Manila, Philippines
🇨🇳
Annexon Investigational Site 101, Taichung City, Taiwan

and more 4 locations

Dose Study of ANX1502 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ANX1502
Drug: Placebo

First Posted Date: 2022-08-30

Last Posted Date: 2024-12-27

Lead Sponsor: Annexon, Inc.

Target Recruit Count: 135

Registration Number: NCT05521269

Locations: 🇳🇱
Annexon Investigational Site 01, Groningen, Netherlands

Single Ascending Dose Study of ANX105

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Biological: ANX105

First Posted Date: 2022-03-21

Last Posted Date: 2024-08-19

Lead Sponsor: Annexon, Inc.

Target Recruit Count: 23

Registration Number: NCT05288881

Locations: 🇳🇱
Annexon Investigational Site 01, Leiden, Netherlands
🇳🇱
Annexon Investigational Site 02, Groningen, Netherlands

Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome

Phase 3

Completed

Conditions: Guillain-Barre Syndrome

Interventions: Drug: ANX005
Drug: Placebo

First Posted Date: 2021-01-08

Last Posted Date: 2024-10-09

Lead Sponsor: Annexon, Inc.

Target Recruit Count: 242

Registration Number: NCT04701164

Locations: 🇧🇩
Dhaka Medical Center, Dhaka, Bangladesh
🇧🇩
National Institute of Neurosciences and Hospital (NINS), Dhaka, Bangladesh
🇵🇭
Baguio General Hospital Medical Center, Baguio, Philippines

and more 8 locations

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)

Phase 2

Completed

Conditions: Warm Autoimmune Hemolytic Anemia (wAIHA)

Interventions: Drug: ANX005

First Posted Date: 2020-12-31

Last Posted Date: 2024-01-19

Lead Sponsor: Annexon, Inc.

Target Recruit Count: 6

Registration Number: NCT04691570

Locations: 🇺🇸
Investigational Site 01, Rochester, Minnesota, United States

A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy

Phase 2

Completed

Conditions: Geographic Atrophy

Interventions: Drug: ANX007
Other: Sham comparator

First Posted Date: 2020-12-07

Last Posted Date: 2024-08-21

Lead Sponsor: Annexon, Inc.

Target Recruit Count: 270

Registration Number: NCT04656561

Locations: 🇦🇺
Site 46, Chatswood, New South Wales, Australia
🇺🇸
Site 13, Edmond, Oklahoma, United States
🇺🇸
Site 28, Saint Petersburg, Florida, United States

and more 50 locations

Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)

Phase 2

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: ANX005

First Posted Date: 2020-09-29

Last Posted Date: 2025-01-06

Lead Sponsor: Annexon, Inc.

Target Recruit Count: 17

Registration Number: NCT04569435

Locations: 🇺🇸
Annexon Investigational Site 03, Tampa, Florida, United States
🇨🇦
Annexon Investigational Site 10, Edmonton, Alberta, Canada
🇨🇦
Annexon Investigational Site 08, Montréal, Quebec, Canada

and more 5 locations

A Single and Multiple Ascending Dose Study of ANX009 in Normal Healthy Volunteers (NHV)

Phase 1

Completed

Conditions: Safety and Tolerability in Healthy Volunteers

Interventions: Drug: ANX009
Drug: Placebo

First Posted Date: 2020-09-02

Last Posted Date: 2021-08-30

Lead Sponsor: Annexon, Inc.

Target Recruit Count: 48

Registration Number: NCT04535752

Locations: 🇦🇺
Site 1, Melbourne, Australia

An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease

Phase 2

Completed

Conditions: Huntington Disease

Interventions: Drug: ANX005

First Posted Date: 2020-08-14

Last Posted Date: 2023-01-31

Lead Sponsor: Annexon, Inc.

Target Recruit Count: 28

Registration Number: NCT04514367

Locations: 🇺🇸
Annexon Investigational Site 04, Washington, District of Columbia, United States
🇺🇸
Annexon Investigational Site 08, Kirkland, Washington, United States
🇺🇸
Annexon Investigational Site 02, Birmingham, Alabama, United States

and more 3 locations

Home Terms & Conditions Privacy Policy